Dr. Thomas Lemarchand performed research in molecular and immunopathology in disease models and worked in pharmaceutical companies, before leveraging this experience in both GLP safety and pharmacology non-GLP studies in CROs. As Director of Digital and Quantitative Pathology at StageBio, Dr. Lemarchand routinely uses in situ hybridization, immunohistochemistry, immunofluorescence and morphometry in studies. He earned his DEDV (DMV) from Nantes University School of Veterinary Medicine in 1992, completed pathology training in 1993 in Montreal and earned his PhD from Louisiana State University in 2000. He became a Diplomate of the European College of Veterinary Medicine in 2015.
Your strategic contact here at StageBio working with drug developers to support the histopathology phase of their programs, ensuring our clients receive high quality, regulatory ready data and reports needed to move confidently toward submission. As a strategic partner, I recognise the sense of urgency, data requirement, and budget pressures our clients face. My role is to connect you with the right experts, help shape study designs aligned to your goals, and make sure all the critical pieces are in place, so your project moves forward quickly and smoothly. My focus is to ensure our clients avoid any common missteps, uncover tailored solutions, and delivery the clarity and precision you need from your tissue-based studies.
Ayse combines strategic business leadership with a strong commitment to long-term client partnerships. She leverages her extensive industry network, operational expertise, and deep understanding of client needs to ensure every project runs efficiently, meets regulatory standards. Ayse is passionate about building trust through transparent communication, proactive and tailored solutions that align with each client’s goals. Under her leadership, StageBio Germany has strengthened its market position, expanded service offerings, and fostered cross-site collaboration, making her a trusted partner for both existing and new clients.
513.204.4400
